Login (or create a FREE account) to register for FREE!
Program Overview
Expand Access to LAIs, Expand Care
Pharmacists can play an instrumental role in the administration of psychotropic long-acting injectable (LAI) medications (antipsychotics, naltrexone, buprenorphine) but may lack the training needed to perform this important service. This multi-faceted, on demand educational activity aims to reduce barriers and increase patient access to LAIs through a universal training program that includes, but is not limited to, appropriate patient selection, LAI preparation and administration techniques, and insights into methods to engage a patient population with serious mental illness.
Disclosure on State Training Requirements
The ability of a pharmacist to administer injectable medications is based on individual state regulations. Each state has its own unique LAI training requirements. Please review the regulations for the state you practice in to determine whether the program meets your needs and whether additional training beyond this program is required prior to administering LAI medications to patients.
Order a print copy of the pocket guide!
Download a certificate of completion after completing all 6 modules.
Be Prepared for LAI Administration
This ACPE approved educational activity includes 5 hours of on demand recorded webinars on psychotropic LAI patient selection, pharmacology, dosing, preparation/administration/storage, key adverse effects and mitigation strategies, and building an LAI practice. Videos on LAI administration are incorporated into the curriculum to enhance learning and real-life application.
Although Risvan® and Rykindo® are not commercially available in the United States, they are included in the course materials because they carry FDA‑approved labeling.
Program Modules
Learn more about the individual on-demand courses by clicking on the modules below!
Introduction to Long-Acting Injectable Antipsychotics and Patient Selection  | Antipsychotic Long-Acting Injectable Pharmacology and Dosing  | Antipsychotic Long-Acting Injectable Preparation, Administration, and Storage  | ||
Antipsychotic Long-Acting Injectable Adverse Effects, Mitigation Strategies, and Monitoring  | Substance Use Disorder Long-Acting Injectables: Naltrexone and Buprenorphine  | Building a Long-Acting Injectable Practice Jerry McKee, PharmD, MS, BCPP, FAAPP  |
Program Support
This activity is supported by an educational grant from Johnson & Johnson.